|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
US20260200925A1
(en)
*
|
2021-11-24 |
2026-07-16 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras mutated proteins
|
|
WO2023172737A1
(en)
|
2022-03-11 |
2023-09-14 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2023320565A1
(en)
|
2022-08-05 |
2025-01-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024032703A1
(en)
*
|
2022-08-11 |
2024-02-15 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
AU2023321005A1
(en)
*
|
2022-08-12 |
2025-03-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Tricyclic compounds and medical use thereof
|
|
TW202434606A
(zh)
*
|
2022-11-17 |
2024-09-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合三環類化合物、其製備方法及其在醫藥上的應用
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2024178304A1
(en)
*
|
2023-02-24 |
2024-08-29 |
Alterome Therapeutics, Inc. |
Kras modulators
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
CR20250413A
(es)
*
|
2023-04-05 |
2025-11-06 |
Pfizer |
Compuestos de pirido[4,3–d]pirimidina
|
|
WO2024218686A1
(en)
*
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
CN121194980A
(zh)
*
|
2023-05-16 |
2025-12-23 |
和记黄埔医药(上海)有限公司 |
三环类化合物及其用途
|
|
EP4724445A1
(en)
|
2023-06-06 |
2026-04-15 |
Kumquat Biosciences Inc. |
Substituted heterocycles and uses thereof
|
|
EP4735451A1
(en)
|
2023-06-30 |
2026-05-06 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025006967A1
(en)
|
2023-06-30 |
2025-01-02 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
AU2024404270A1
(en)
*
|
2023-12-19 |
2026-07-23 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Fused tricyclic compound and medical use thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202608896A
(zh)
*
|
2024-04-30 |
2026-03-01 |
大陸商和記黃埔醫藥(上海)有限公司 |
抗體藥物偶聯物及其用途
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
TW202615038A
(zh)
|
2024-08-07 |
2026-04-16 |
美商太斯萊特醫藥美國有限責任公司 |
包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN119874616B
(zh)
*
|
2025-03-28 |
2025-05-30 |
四川美域高生物医药科技有限公司 |
一种有机中间体及其制备方法和应用
|